INS and sarcopenia: After adjusting confounding factors (DN, DR, DPN, DF, history of insulin use, history of biguanides use, history of thiazolidines use, history of antihypertensive drugs use, history of hypertension use, ACR, TC, TG, HDL, LDL, eGFR, P, Ca, HbA1c, serum C peptide), we found: compared with NOT2D, people with EOT2D are at greater risk of developing sarcopenia, osteoporosis and even musculoskeletal damage (sarcopenia: P<0.001, OR= 7.802, 95%CI: 5.131~11.865; osteoporosis: P= 0.017, OR= 1.814, 95%CI: 1.110~2.964; musculoskeletal damage: P<0.001, OR= 4.705, 95%CI: 3.241~6.832).